Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nanoparticles: Facilitating Targeted Drug Delivery in Cancer Therapy
Engineering nanoparticles with optimal properties for use in cancer therapies.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 48-52

References

1. M. Morgen et al., Pharm. Res. 29 (2) 427-440 (2012).

2. A. Siew et al., Mol. Pharm. 9 (1) 14-28 (2012).

3. C. Liu et al., Biomat. 34 (10) 2547-2564 (2013).

4. I. Altintas et al., J. Control. Rel. 165 (2) 110-118 (2013).

5. W.Y. Qian et al., Int. J. Nanomed. 7: 5781-5792 (2012).

6. J.H. Sung, D. Han, and J.B. Lee, Biotechnol. J. 8 (2) 215-220 (2013).

7. C.Y. Dombu and D. Betbeder, Biomat. 34 (2) 516-525 (2013).

8. S. Hauptstein and A. Bernkop-Schnurch, Expert. Opin. Drug Deliv. 9 (9) 1069-1081 (2012).

9. R. Singh and J.W. Lillard, Exp. Mol. Pathol. 86 (3) 215-223 (2009).

10. A.Z. Wang, R. Langer, and O.C. Farokhzad, Annu. Rev. Med. 63: 185-198 (2012).

11. A. Swami et al., "Nanoparticles for targeted and temporally controlled drug delivery," in Multifunctional Nanoparticles for Drug Delivery Applications, S. Svenson and R.K. Prud'homme, Eds. (Springer, US, 2012), pp. 9-29.

12. NanoCarrier, "NC-6004 Nanoplatin," http://www.nanocarrier.co.jp/en/research/pipeline accessed Feb. 8, 2013.

13. H. Uchino et al., Br. J. Cancer 93 (6) 678-687 (2005).

14. R. Plummer et al., Br. J. Cancer 104 (4) 593-598 (2011).

15. Cerulean, "CRLX101," http://ceruleanrx.com/, accessed Feb. 8, 2013.

16. Young et al., Curr. Bioact. Compd. 7 (1) 8-14 (2011).

17. T. Hamaguchi et al., Br. J. Cancer 92 (7) 1240-1246 (2005).

18. Zhang et al., Adv. Funct. Mat. 22 (24) 5144-5156 (2012).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here